Cyclic Peptide αVβ3 Integrin Binding Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammation lack effective solutions for chronic and acute inflammatory diseases, particularly those not related to cancer, osteoporosis, rheumatic arthritis, or angiogenesis-related eye diseases, and often fail to address the underlying mechanisms of inflammation such as type I interferon activity.
Innovation Solution
Administration of a therapeutically effective amount of a cyclic peptide that binds to the αVβ3 integrin, specifically selected from sequences like SEQ ID NOs: 11-15, to reduce inflammation in diseases like atherosclerosis and graft rejection, which are not associated with cancer, osteoporosis, rheumatic arthritis, or angiogenesis-related eye diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-inflammatory treatments are used, then general inflammatory symptoms are addressed, but they fail to effectively treat chronic and acute inflammatory diseases not related to cancer, osteoporosis, rheumatic arthritis, or angiogenesis-related eye diseases
Solution Approach 1:
The patent applies local quality by developing specific peptide sequences (SEQ ID NOs: 11-15) tailored for particular inflammatory conditions. These peptides are designed with specific amino acid compositions that target type I interferon activity and inflammatory marker expression in a disease-specific manner, rather than using broad-spectrum anti-inflammatory agents.
Solution Approach 2:
The patent employs parameter changes by modifying peptide sequences to optimize their anti-inflammatory activity. The specific amino acid sequences are engineered to achieve desired binding affinity and biological activity, allowing differentiation between various inflammatory disease targets while maintaining selectivity.
2Adaptability or versatility
If broad-spectrum anti-inflammatory agents are administered, then multiple inflammatory conditions are covered, but underlying mechanisms such as type I interferon activity are not effectively addressed
Solution Approach 1:
The patent segments the anti-inflammatory approach by dividing it into specific peptide agents targeting different inflammatory pathways. Rather than using a single broad-spectrum agent, the invention provides distinct peptide sequences that can be selected based on the specific inflammatory mechanism involved, such as type I interferon activity.
Solution Approach 2:
The patent uses peptide agents as intermediaries that specifically mediate between the administration route and the inflammatory targets. These peptides act as selective mediators that can specifically inhibit type I interferon activity and reduce inflammatory marker expression without affecting other physiological processes.
3Reliability
If specific peptide sequences are used to target type I interferon activity, then underlying inflammatory mechanisms are effectively addressed, but treatment is limited to specific inflammatory diseases
Solution Approach 1:
The patent achieves universality by demonstrating that the specific peptide sequences (SEQ ID NOs: 11-15) can be applied across multiple inflammatory disease types. The peptides are designed to target fundamental inflammatory mechanisms (type I interferon activity, inflammatory marker expression) that are common across different inflammatory conditions, allowing one agent to serve multiple therapeutic purposes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively suppresses interferon type I signaling and reduces inflammatory marker expression, demonstrating significant anti-inflammatory effects in treating chronic and acute inflammatory conditions.
Implementation Method 1
a cyclic peptide that binds to the αVβ3 integrin
Data Source
AI summary
A method of treating an inflammatory disease or disorder is disclosed. The method comprises administering to the subject a therapeutically effective amount of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11-15. The inflammatory disease is not cancer, osteoporosis, rheumatic arthritis, osteoarthritis or angiogenesis-related eye disease.